Published in Clin Cancer Res on March 01, 2006
DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 2.56
DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair (Amst) (2007) 1.36
Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharm Stat (2013) 1.26
Interactions of human O6-alkylguanine-DNA alkyltransferase (AGT) with short single-stranded DNAs. J Biol Chem (2006) 1.19
DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem (2008) 1.17
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer (2009) 0.95
Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med (2012) 0.95
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res (2011) 0.94
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol (2013) 0.93
Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res (2008) 0.92
Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) (2007) 0.92
Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT). Nucleic Acids Res (2006) 0.90
Interactions of human O(6)-alkylguanine-DNA alkyltransferase (AGT) with short double-stranded DNAs. Biochemistry (2008) 0.90
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer (2008) 0.89
Topologies of complexes containing O6-alkylguanine-DNA alkyltransferase and DNA. J Mol Biol (2009) 0.86
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res (2010) 0.85
Cooperative cluster formation, DNA bending and base-flipping by O6-alkylguanine-DNA alkyltransferase. Nucleic Acids Res (2012) 0.85
Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase. Biochem Pharmacol (2007) 0.83
Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. Future Med Chem (2012) 0.83
Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine. J Med Chem (2007) 0.82
Mutations that probe the cooperative assembly of O⁶-alkylguanine-DNA alkyltransferase complexes. Biochemistry (2011) 0.82
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer (2011) 0.82
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer (2009) 0.82
Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. J Med Chem (2008) 0.80
Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol (2013) 0.79
Antineoplastic effect of decoy oligonucleotide derived from MGMT enhancer. PLoS One (2014) 0.75
Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU. ACS Med Chem Lett (2017) 0.75
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res (2009) 0.75
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet (2003) 8.30
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst (2013) 3.63
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol (2013) 3.11
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol (2013) 2.22
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol (2003) 1.90
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther (2005) 1.82
Flipping of alkylated DNA damage bridges base and nucleotide excision repair. Nature (2009) 1.70
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Mycoplasma infection significantly alters microarray gene expression profiles. Biotechniques (2003) 1.66
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys (2006) 1.48
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J (2006) 1.38
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res (2005) 1.37
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev (2005) 1.36
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell (2013) 1.28
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol (2013) 1.28
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest (2011) 1.27
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull (2008) 1.21
Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer (2012) 1.21
Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci (2010) 1.20
A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer (2002) 1.20
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol (2009) 1.19
Optobionic vision--a new genetically enhanced light on retinal prosthesis. J Neural Eng (2009) 1.18
Lifestyle and quality of life in colorectal cancer survivors. Qual Life Res (2011) 1.17
Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.16
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol (2003) 1.12
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis (2007) 1.04
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res (2012) 1.03
Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer (2007) 1.01
DNA repair pathways in drug resistance in melanoma. Anticancer Drugs (2004) 0.98
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol (2012) 0.98
A novel DNA damage recognition protein in Schizosaccharomyces pombe. Nucleic Acids Res (2006) 0.98
The response of HIV-associated lymphadenopathic Kaposi sarcoma to highly active antiretroviral therapy evaluated by 18F-FDG PET/CT. Clin Nucl Med (2012) 0.97
Inhibition of O6-methylguanine-DNA methyltransferase by an alkyltransferase-like protein from Escherichia coli. Nucleic Acids Res (2005) 0.97
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest (2003) 0.96
Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer. J Clin Oncol (2006) 0.95
Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4. Mol Ther (2004) 0.94
Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther (2004) 0.94
Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res (2008) 0.92
DNA alkylation and repair in the large bowel: animal and human studies. J Nutr (2002) 0.90
Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT). Nucleic Acids Res (2006) 0.90
Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman's disease. Haematologica (2010) 0.90
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer (2002) 0.90
Atl1 regulates choice between global genome and transcription-coupled repair of O(6)-alkylguanines. Mol Cell (2012) 0.90
Glucarpidase following high-dose methotrexate: update on development. Expert Opin Biol Ther (2010) 0.89
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res (2012) 0.89
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol (2006) 0.89
Obesity and hepatosteatosis in mice with enhanced oxidative DNA damage processing in mitochondria. Am J Pathol (2011) 0.89
Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol (2010) 0.89
Alkyltransferase-like protein (Atl1) distinguishes alkylated guanines for DNA repair using cation-π interactions. Proc Natl Acad Sci U S A (2012) 0.89
Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum Gene Ther (2004) 0.88
R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int (2010) 0.88
Convenient and efficient syntheses of oligodeoxyribonucleotides containing O(6)-(carboxymethyl)guanine and O(6)-(4-oxo-4-(3-pyridyl)butyl)guanine. Nucleosides Nucleotides Nucleic Acids (2012) 0.87
A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res (2003) 0.87
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase. J Med Chem (2012) 0.87
Elevated N3-methylpurine-DNA glycosylase DNA repair activity is associated with lung cancer. Mutat Res (2012) 0.86
Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound. Ultrasound Med Biol (2004) 0.86
Flexible blue-emitting encapsulated organic semiconductor DFB laser. Opt Express (2010) 0.85
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res (2010) 0.85
Reduced MGMT activity in human colorectal adenomas is associated with K-ras GC->AT transition mutations in a population exposed to methylating agents. Carcinogenesis (2004) 0.85
Association between lung cancer risk and single nucleotide polymorphisms in the first intron and codon 178 of the DNA repair gene, O6-alkylguanine-DNA alkyltransferase. Int J Cancer (2008) 0.84
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol (2003) 0.84
The nitrosated bile acid DNA lesion O6-carboxymethylguanine is a substrate for the human DNA repair protein O6-methylguanine-DNA methyltransferase. Nucleic Acids Res (2013) 0.83
Associations between tissue-specific DNA alkylation, DNA repair and cell proliferation in the colon and colon tumour yield in mice treated with 1,2-dimethylhydrazine. Carcinogenesis (2003) 0.83
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol (2012) 0.83
Bladder tumor contains higher N7-methylguanine levels in DNA than adjacent normal bladder epithelium. Cancer Epidemiol Biomarkers Prev (2006) 0.83
Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis. Mutat Res (2013) 0.83
The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J Gene Med (2006) 0.82
Heterogeneity of O(6)-alkylguanine-DNA alkyltransferase activity in colorectal cancer: implications for treatment. Oncology (2002) 0.81
Folate deficiency alters hepatic and colon MGMT and OGG-1 DNA repair protein expression in rats but has no effect on genome-wide DNA methylation. Cancer Prev Res (Phila) (2010) 0.81
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res (2015) 0.81
Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol (2008) 0.80
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol (2014) 0.80
Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. Mol Ther (2004) 0.80
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther (2004) 0.80